EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Prediction of 177 Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study

Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, Carlos Artigas, Camille Van Bogaert, Clémentine Marin, Rachele Danieli, Amelie Deleporte, Simona Picchia, Konstantinos Stathopoulos, Christiane Jungels, Bruno Vanderlinden und 10 weitere

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.265987 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Magdalena Mileva und 21 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Br…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Organometallic Compounds, Stomach Neoplasms, Pancreatic Neoplasms. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our objective was to predict the outcome of peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine tumor (GEP-NET) lesions and patients.

Methods

This prospective study included patients with progressive GEP-NETs. Treatment consisted of 4 cycles of 7.4 GBq of 177Lu-DOTATATE. Imaging parameters were measured on 68Ga-DOTATATE PET/CT (SUVmax/mean, somatostatin receptor [SSTR] tumor volume [TV], total lesion SSTR expression, and tumor-to-blood and tumor-to-spleen ratios), 18F-FDG PET/CT (SUVmax/mean, metabolically active TV, and total lesion glycolysis), and diffusion-weighted MRI (apparent diffusion coefficient) in a maximum of 5 target lesions per patient at approximately 10 wk after each injection. Tumor dosimetry was performed using SPECT/CT at 3 time points for every cycle. Baseline imaging parameters, their relative changes after PRRT cycle 1 (C1), and the tumor-absorbed dose at C1 were correlated with lesion morphologic outcome. The average values of the imaging parameters and the minimal, maximal, and mean C1 tumor-absorbed dose in each patient were tested for association with progression-free survival (PFS) and best objective response (RECIST 1.1).

Results

In the 37 patients, the median PFS was 28 mo. Eleven of the 37 (30%) achieved a partial response (RECIST 1.1). After a median follow-up of 57 mo, the median time to lesion progression had not been reached in 84 morphologically evaluable lesions, with only 12 (14%) progressing (size increase ≥ 20% from baseline). Patients receiving a minimal C1 dose of 35 Gy in all target lesions exhibited a significantly longer PFS (48.1 vs. 26.2 mo; hazard ratio, 0.37; 95% CI, 0.17-0.82; P = 0.02). Volumetric 68Ga-DOTATATE PET parameters correlated with lesion and patient outcome: patients with an SSTR TV decrease of more than 10% after C1 had a longer PFS (51.3 vs. 22.8 mo; hazard ratio, 0.35; 95% CI, 0.16-0.75; P = 0.003). There was no statistical evidence of an association between other dosimetric or imaging parameters and the lesion or patient outcome.

Conclusion

Minimal tumor-absorbed dose at C1 is predictive of outcome in patients with GEP-NETs treated with PRRT, providing a basis for personalized dosimetry-guided treatment strategies. An SSTR TV decrease after C1 could be used for early therapy response assessment as a predictor of PRRT outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOrganometallic CompoundsStomach NeoplasmsPancreatic NeoplasmsIntestinal NeoplasmsPositron-Emission TomographyRadionuclide ImagingHumansPositron Emission Tomography Computed TomographyProspective StudiesGallium RadioisotopesTreatment OutcomeReceptors, SomatostatinOctreotide

Stichwörter der Autor:innen

68Ga-DOTATATEdosimetryneuroendocrine tumorspeptide receptor radionuclide therapyresponse prediction

Substanzen

copper dotatate CU-64Gallium RadioisotopesOrganometallic CompoundsReceptors, SomatostatinOctreotide

Autor:innen und Institutionen

  • Nuclear Medicine Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
  • Medical Physics Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
  • Nuclear Medicine Department, CUB-Hôpital Erasme, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
  • Medical Oncology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
  • Radiology Department, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
  • Data Center, Institut Jules Bordet, ENETS Centre of Excellence, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; and.

Zitieren

APA

Mileva, M., Marin, G., Levillain, H., Artigas, C., Van Bogaert, C., Marin, C., Danieli, R., Deleporte, A., Picchia, S., Stathopoulos, K., Jungels, C., Vanderlinden, B., Paesmans, M., Ameye, L., Critchi, G., Taraji-Schiltz, L., Velghe, C., Wimana, Z., Bali, M., …, & Karfis, I. (2024). Prediction of 177 Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265987

Vancouver

Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al. Prediction of 177 Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.265987

BibTeX
@article{Mileva2024,
  author = {Mileva, Magdalena and Marin, Gwennaëlle and Levillain, Hugo and Artigas, Carlos and Van Bogaert, Camille and Marin, Clémentine and Danieli, Rachele and Deleporte, Amelie and Picchia, Simona and Stathopoulos, Konstantinos and Jungels, Christiane and Vanderlinden, Bruno and Paesmans, Marianne and Ameye, Lieveke and Critchi, Gabriela and Taraji-Schiltz, Loubna and Velghe, Chloe and Wimana, Zéna and Bali, Maria and Hendlisz, Alain and Flamen, Patrick and Karfis, Ioannis},
  title = {Prediction of 177 Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.265987}
}
Kostenlos starten →